Stocktoria
Lunai Bioworks Inc. LNAI
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-11-18
Lunai Bioworks Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $537,428 | $2.7M | $4.2M | $8.4M | $15.7M |
| Operating income | -$189.0M | -$81.6M | -$38.6M | -$116.1M | -$23.4M |
| Interest expense | — | — | — | $372,844 | $379,608 |
| Income tax | $1,474 | $0 | — | $34 | -$125,276 |
| Net income | -$178.0M | -$88.4M | -$39.7M | -$113.4M | -$26.7M |
| EPS (diluted) | $-1.08 | $-0.91 | $-0.71 | $-2.16 | — |
| Operating cash flow | -$7.9M | -$11.0M | -$11.8M | -$15.7M | -$20.6M |
| Free cash flow | — | -$11.0M | -$11.8M | -$15.7M | -$20.7M |
| Cash & equivalents | $92,700 | $220,467 | $1.9M | $9.2M | $20.7M |
| Total assets | $8.2M | $163.1M | $58.3M | $84.6M | $189.6M |
| Total liabilities | $29.6M | $31.2M | $11.8M | $12.0M | $14.9M |
| Shareholders' equity | -$21.3M | $132.0M | $46.5M | $72.6M | $174.7M |
Source: SEC EDGAR filings · CIK 0001527728 · as of 2025-06-30. Facts from filings plus Stocktoria's own computed scores — not investment advice.